Assessment of Costs and Benefits of Drug Therapy for Treatment-Resistant Schizophrenia in the United Kingdom
Assessment of Costs and Benefits of Drug Therapy for Treatment-Resistant Schizophrenia in the United Kingdom
复制标题
英国难治性精神分裂症药物治疗的成本和效益评估
DOI：
--
复制
发表时间：
1993
影响因子：
10.5
通讯作者：
M. Drummond
中科院分区：
文献类型：
--
作者：
Linda M. Davies;M. Drummond
在现有数据的基础上进行了分析，以评估长期住院机构或工作人员团体之家中的中度至重度精神分裂症患者使用氯氮平治疗的经济后果，以估计该药物的可能成本和收益。在美国进行的成本效益研究的数据，辅以其他文献来源，用于构建此类患者可能临床结局的临床决策树。一个由英国精神病学家组成的小组就这些患者在英国如何管理达成了共识。估计与每个患者结局相关的成本，并进行敏感性分析以测试所做的假设。对于患者本身，氯氮平将导致净增加5.87年的寿命，没有残疾或只有轻度残疾。基础病例分析显示，当考虑到对所有卫生保健资源的影响时，使用氯氮平的直接成本比标准抗精神病药物治疗每年少91英镑（或一生少1333英镑）。此外，敏感性分析表明，氯氮平将节省成本或成本中性在许多不同的假设。一项关于氯氮平治疗精神分裂症的前瞻性卫生经济学研究将有助于证实这些结果。
An analysis was conducted on the basis of available data to assess the economic consequences of clozapine therapy for people with moderate to severe schizophrenia in long-stay institutions or staffed group homes, with a view to providing an estimate of the likely costs and benefits of the drug. Data from a cost-effectiveness study conducted in the US, supplemented by other literature sources, were used to construct a clinical decision tree for likely clinical outcomes for such patients. A panel of UK psychiatrists provided consensus on how these patients would have been managed in the UK. The costs associated with each patient outcome were estimated, and a sensitivity analysis performed to test the assumptions made. For the patients themselves, clozapine would lead to a net gain of 5.87 years of life with no disability or only mild disability. The base case analysis showed that the direct costs of using clozapine were £91 less per annum (or £1333 per lifetime) than for standard neuroleptic therapy, when the effect on all health-care resources was taken into account. In addition, the sensitivity analysis showed that clozapine would be cost-saving or cost-neutral under many different assumptions. A prospective health economic study with clozapine in the management of schizophrenia would be desirable to confirm these results.
影响因子：
--
作者：
J. Kane;G. Honigfeld;J. Singer;H. Meltzer
通讯作者：
J. Kane;G. Honigfeld;J. Singer;H. Meltzer